Global Melanoma Therapeutics Market Trends, Analysis, Growth, and Forecast: 2017 to 2026

MarketResearch.biz delivers in-depth insights on the global melanoma therapeutics market in its upcoming report titled, “Global Melanoma Therapeutics Market Trends, Analysis, Growth, and Forecast: 2017 to 2026”. The global melanoma therapeutics market is estimated to register a CAGR of X.X% in terms of value during forecast period 2017–2026. The report offers in-depth insights, revenue details, and other vital information regarding the global melanoma therapeutics market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2026. The report offers insightful and detailed information regarding the various key players operating in the global melanoma therapeutics market, their financials, supply chain trends, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global melanoma therapeutics market report has been segmented on the basis of therapy type, stage, and region.

Melanoma is a form of skin cancer that arises when pigment-producing cells mutates and become cancerous. Pigmented cells are found in skin and occur in other part of body such as intestine, and eyes. Melanoma is one of type of skin cancer which is less common than basal cell and squamous cell skin cancer. However, melanoma is considered as dangerous type of skin cancer as these cancerous growths develop when unrepaired DNA damage to skin cells and they are likely to spread in the body. Melanoma is caused due to exposure to ultraviolet radiation form the sun and from tanning lamp.

Increasing prevalence of melanoma, skin allergies and skin cancer is expected to drive the growth of melanoma therapeutics market. Moreover, rising awareness about the melanoma globally, coupled with several government and non-profit organizations providing education and support services is anticipated to further drive growth of the global melanoma therapeutics market over the forecast period. Furthermore, increasing number of approvals for novel therapeutics is expected to boost the growth of melanoma therapeutics market over the forecast period.

A major factor restraining growth of the global melanoma therapeutics market is high cost for treatment.

However, technological advancements and innovations focusing on development of biologics for treatments is expected to create new opportunities for major players in the global melanoma therapeutics market over the forecast period.

North America market dominates the global melanoma therapeutics market in terms of revenue contribution as compared to that of markets in other regions. This is attributed to well-developed healthcare infrastructure and availability of skilled medical personnel and increasing number of skin cancer cases in the region. Europe accounts for second-largest revenue share contribution to the global melanoma therapeutics market, followed by markets in Latin America, Asia Pacific, and Middle East & Africa respectively. The market in Asia Pacific is projected to register comparatively faster growth in terms of revenue over the next 10 years, owing to increasing investment by key market players in emerging market and increasing demand for cost-efficient therapeutics.

Global melanoma therapeutics market segmentation, by therapy type:

• Chemotherapy
• Targeted therapy
• Radiation therapy
• Immunotherapy
• Other novel therapies (Virus based, Adjuvant therapy)

Global melanoma therapeutics market segmentation, by stage:

• Stage 0 (Melanoma in Situ)
• Stage I
• Stage II
• Stage III
• Stage IV

Global melanoma therapeutics market segmentation, by region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

• Amgen, Inc.
• Hoffman-La Roche Ltd.
• Bristol-Myers Squibb Company
• Novartis AG
• Merck & Co., Inc.
• AstraZeneca
• AB Sciences
• Celgene Corporation
• Galectin Therapeutics
• Ziopharm Oncology, Inc.